Safety and Immunogenicity of an mRNA-1273 Booster in Children
Author Information
Author(s): Berthaud Vladimir, Creech C Buddy, Rostad Christina A, Carr Quito, de Leon Liberation, Dietrich Monika, Gupta Anil, Javita David, Nachman Sharon, Pinninti Swetha, Rathore Mobeen, Rodriguez Carina A, Luzuriaga Katherine, Towner William, Yeakey Anne, Brown Mollie, Zhao Xiaoping, Deng Weiping, Xu Wenqin, Zhou Honghong, Girard Bethany, Kelly Roxanne, Slobod Karen, Anderson Evan J, Das Rituparna, Miller Jacqueline, Schnyder Ghamloush Sabine
Primary Institution: Moderna, Inc
Hypothesis
Does an mRNA-1273 booster dose improve immune response in children aged 6 months to 11 years?
Conclusion
The mRNA-1273 booster dose is safe and elicits strong immune responses in children aged 6 months to 11 years.
Supporting Evidence
- The booster dose safety profile was consistent with the primary series.
- Robust neutralizing antibody responses were observed post-booster.
- Noninferiority criteria were met for immune responses compared to young adults.
- Adverse events were mostly mild to moderate.
- No new safety concerns were identified.
Takeaway
Giving a booster shot of the mRNA-1273 vaccine to kids helps their bodies fight off COVID-19 better.
Methodology
Participants received an mRNA-1273 booster dose 6 months after the primary series, and their immune responses were measured.
Potential Biases
Potential conflicts of interest due to authors' affiliations with Moderna, Inc.
Limitations
The study had a limited sample size and may not detect rare safety events.
Participant Demographics
Participants included 153 children aged 6 months to 5 years and 2519 children aged 6 to 11 years, with a majority being White.
Statistical Information
P-Value
3.9
Confidence Interval
95% CI: 3.2–4.8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website